Head and Neck Cancer Drugs Market to Grow with a CAGR of 5.69% through 2028
Increasing incidence of head and neck cancer and expanding strong
pipeline of new drugs are factors driving the global Head and Neck Cancer Drugs
market in the forecast period 2024-2028.
According to TechSci Research report, “Head and
Neck Cancer Drugs Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Head
and Neck Cancer Drugs Market stood at USD 1.95 billion in 2022 and is
anticipated to grow with a CAGR of 5.69% in the forecast period, 2024-2028. Head and neck cancer is a group of cancers that occur in the mouth,
throat, nose, sinuses, and salivary glands. It is a significant global health
concern, with millions of people affected each year. The treatment landscape
for head and neck cancer has evolved significantly in recent years, thanks in
large part to the development of innovative drugs. One of the
primary drivers of the global head and neck cancer drugs market is the rising
incidence of these cancers worldwide. Factors such as tobacco and alcohol
consumption, as well as infection with human papillomavirus (HPV), are
contributing to the increasing prevalence of head and neck cancer. This growing
patient population necessitates the development and availability of effective
drugs to combat the disease. The
pharmaceutical industry has made significant strides in understanding the
molecular and genetic underpinnings of head and neck cancer. This improved
understanding has led to the identification of novel drug targets and the
development of targeted therapies. Targeted therapies are more precise in their
action and tend to have fewer side effects compared to traditional
chemotherapy, making them a preferred choice for both patients and healthcare
providers.
Immune checkpoint inhibitors have
revolutionized the treatment of various cancers, including head and neck
cancer. Drugs like pembrolizumab and nivolumab have demonstrated remarkable
efficacy in clinical trials, leading to their approval for the treatment of
recurrent or metastatic head and neck squamous cell carcinoma. The success of
immune checkpoint inhibitors has created a significant market for these drugs,
and ongoing research is expected to expand their applications further. Advancements in genomics and molecular
diagnostics have ushered in an era of personalized medicine. Patients with head
and neck cancer can now undergo genetic testing to identify specific mutations
or biomarkers that may respond to targeted therapies. This tailored approach to
treatment not only improves patient outcomes but also contributes to the growth
of the head and neck cancer drugs market, as pharmaceutical companies invest in
developing drugs that target these specific biomarkers. The Global Head and Neck Cancer Drugs Market is
segmented into drug class, distribution channel and company.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Head and Neck Cancer Drugs Market.”
Based on drug class, the immunotherapy segment has
emerged as the predominant market leader. Immunotherapy specifically targets cancer cells,
sparing healthy tissues, which reduces the risk of collateral damage and
related side effects. Researchers are exploring the potential of combining
immunotherapy with other treatment modalities like radiation therapy and
targeted therapies to enhance its effectiveness. Based on region, North America segment is expected to
grow during the forecast period. North America boasts a
well-developed healthcare infrastructure, characterized by state-of-the-art
medical facilities, well-trained healthcare professionals, and advanced
diagnostic and treatment technologies. This infrastructure supports the rapid
development and delivery of novel cancer drugs and therapies. Patients in North
America have access to some of the world's most advanced treatments and
clinical trials, fostering an environment conducive to progress in head and
neck cancer care. The Asia Pacific
region is experiencing rapid market growth. The region fosters collaboration
between government agencies, research institutions, pharmaceutical companies,
and advocacy groups. These collaborative efforts accelerate the development and
adoption of new therapies.
Major companies operating in Global Head and Neck
Cancer Drugs Market are:
- Merck & Co., Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Astrazeneca Plc.
- Fresenius Medical Care AG & CO. KGAA
- F.Hoffmann-la Roche Ltd. (Genentech, Inc.,)
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global head and neck cancer drugs market is
poised for significant growth in the coming years, driven by factors such as
the increasing incidence of the disease, advancements in research and
development, the rise of immune checkpoint inhibitors, personalized medicine
approaches, a strong drug pipeline, government support, and growing awareness.
As pharmaceutical companies continue to innovate and bring new therapies to
market, patients with head and neck cancer can look forward to improved
treatment options and better outcomes.,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Head and Neck Cancer Drugs Market By Drug Class
(Chemotherapy, Immunotherapy, Targeted Therapy), By Distribution Channel
(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, By
Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Head and Neck Cancer Drugs Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Head and Neck Cancer Drugs Market.
Contact
Mr. Ken Mathews
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel:
+13322586602
Email:
[email protected]
Website:
www.techsciresearch.com